“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.

• Idiopathic Pulmonary Fibrosis companies working in the treatment market are Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment

• Emerging Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.

• In September 2025, PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company focused on advancing innovative science into impactful treatments, shared new data from the open-label extension (OLE) of its Phase 2b ELEVATE IPF trial evaluating deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF). Results revealed that participants who had previously received placebo or pirfenidone for 26 weeks in the randomized phase and then transitioned to deupirfenidone for another 26 weeks in the OLE showed stabilized lung function. Presented as a late-breaking oral session at the 2025 European Respiratory Society (ERS) Congress in Amsterdam, these outcomes underscore deupirfenidone’s potential as a future standard of care in IPF treatment.

• In September 2025, United Therapeutics is seeking approval for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) following positive results from a Phase III trial. In the TETON-2 study (NCT05255991), the inhaled prostacyclin mimetic significantly improved forced vital capacity (FVC), showing a 95.6 mL increase from baseline. Since FVC is a crucial indicator of breathing restriction in IPF, this outcome is notable. Additionally, the systemic vasodilator delayed the time to the first clinical worsening event, achieving its key secondary endpoint.

• In May 2025, Endeavor BioMedicines, a clinical-stage biotech company developing treatments for serious conditions, presented a post hoc analysis from its completed Phase 2a trial of the investigational drug ENV-101 (taladegib). The findings indicated that patients with idiopathic pulmonary fibrosis (IPF) treated with ENV-101 for 12 weeks showed a marked reduction in pulmonary vessel volume, a significant increase in lung volume, and a trend toward decreased lung fibrosis compared to placebo. This analysis, utilizing Qureight’s advanced deep learning CT technology, was highlighted in a poster presentation at the ATS 2025 International Conference.

• In February 2025, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has temporarily halted enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) following a prespecified data review and recommendations from the independent Data Safety Monitoring Board (DSMB). However, patients already enrolled will continue participation in the trial.

• In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody designed to inhibit WISP1-driven fibrotic signaling associated with multiple severe diseases.

• In December 2024, Boston-based clinical-stage biotherapeutics company PureTech announced that its Phase IIb trial of deupirfenidone successfully met all primary and secondary endpoints, demonstrating a reduction in lung function decline in patients with idiopathic pulmonary fibrosis (IPF). The dose-ranging study assessed deupirfenidone (LYT-100) over 26 days, revealing that the high dose effectively slowed lung degeneration. PureTech aims to position the therapy as a new standard of care (SOC) for IPF

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, and progressive lung disease where scar tissue (fibrosis) builds up in the lungs without a known cause. This scarring makes the lungs stiff, reducing their ability to deliver oxygen to the bloodstream. Symptoms include shortness of breath, dry cough, fatigue, and reduced exercise capacity. Over time, IPF worsens and can lead to respiratory failure.

Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

• BI 1015550: Boehringer Ingelheim

• OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH

• Pirfenidone: PureTech

• SC1011: Guangzhou JOYO Pharma

• TTI-101: Tvardi Therapeutics

• PLN-74809: Pliant Therapeutics, Inc.

• GSK3915393: GlaxoSmithKline

• HZN-825: Amgen

• BMS-986278: Bristol-Myers Squibb

• taladegib: Endeavor Biomedicines

• BI 1819479: Boehringer Ingelheim

• Axatilimab: Syndax Pharmaceuticals

• REGEND001: Regend Therapeutics

Idiopathic Pulmonary Fibrosis Route of Administration

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Idiopathic Pulmonary Fibrosis Molecule Type Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

• Monoclonal

• Antibody Peptides

• Polymer

• Small molecule

• Gene therapy

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

• Idiopathic Pulmonary Fibrosis Assessment by Product Type

• Idiopathic Pulmonary Fibrosis By Stage and Product Type

• Idiopathic Pulmonary Fibrosis Assessment by Route of Administration

• Idiopathic Pulmonary Fibrosis By Stage and Route of Administration

• Idiopathic Pulmonary Fibrosis Assessment by Molecule Type

• Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Idiopathic Pulmonary Fibrosis Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Idiopathic Pulmonary Fibrosis are – United Therapeutics, Bellerophon Therapeutics, and MediciNova, and others.

Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Idiopathic Pulmonary Fibrosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.

• Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies

Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

• Rising prevalence of IPF worldwide, particularly in aging

• populations, driving demand for new therapies.

• Advancements in diagnostics leading to earlier and more accurate disease detection.

• Strong research and development investments by pharmaceutical companies targeting novel antifibrotic and immunomodulatory mechanisms.

• Regulatory support for orphan drugs, accelerating approvals and incentivizing innovation

Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

• Unclear disease etiology and complex pathophysiology make drug development challenging

• High failure rate in clinical trials due to limited efficacy or safety issues

• Expensive development costs for orphan disease therapies, affecting smaller biotech players

• Limited patient population makes recruitment for large-scale trials difficult

• Side effects of existing antifibrotic drugs hinder patient adherence

• Regulatory challenges in proving long-term efficacy and safety of emerging therapies

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

• Coverage: Global

• Key Idiopathic Pulmonary Fibrosis Companies: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others

• Key Idiopathic Pulmonary Fibrosis Therapies: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others

• Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies

• Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Idiopathic Pulmonary Fibrosis Report Introduction

2. Idiopathic Pulmonary Fibrosis Executive Summary

3. Idiopathic Pulmonary Fibrosis Overview

4. Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Idiopathic Pulmonary Fibrosis Key Companies

14. Idiopathic Pulmonary Fibrosis Key Products

15. Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/